Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
This Month's Featured Story The Often-Missed Corner of Healthcare That Wall Street Is LovingSubmitted by Nathan Reiff. Publication Date: 3/29/2026. 
Key Points - Numerous lab equipment stocks are down in the high-teens so far this year, but seemingly modest sales growth may hide fundamental strengths.
- These companies can present a more secure approach to the healthcare industry than some higher-risk alternatives.
- Still, headwinds including tariff impacts and inflation remain a concern.
- Special Report: Elon Musk: This Could Turn $100 into $100,000
The healthcare industry is notoriously volatile—company fortunes can be made or broken on the success of a single product or the results of a clinical trial—and it's not uncommon for stocks in this sector to register some of the widest swings in the market. Investors who want exposure to the healthcare space but are wary of that turbulence may adopt a "picks and shovels" strategy focused on companies that provide essential equipment and services to the industry rather than on higher-risk names in pharmaceuticals, for example. Lab equipment stocks are often overlooked by investors considering healthcare, even though several firms in this subindustry rank among the largest in the space. Given the range of external factors that could affect healthcare companies in 2026—shifting subsidies, an aging population with greater needs, inflation, the growing role of AI, and more—core lab equipment names may look especially attractive. The companies below are some of the major players worth a closer look for any investor examining this industry. A Recent Dip Masks Thermo Fisher's Long-Term Strengths A humanoid robot called Figure 03 escorted First Lady Melania Trump at a White House tech summit attended by CEOs and representatives from 45 countries. Alpha School, a private institution replacing teachers with AI, is now expanding to 35 cities with Department of Education support - and its students are scoring in the top 0.1% nationally. Jamie Dimon, Larry Fink, and Senator Mark Warner are all warning about mass job displacement. One historian is predicting a permanent underclass as automation accelerates. History shows these shifts also create rare wealth-building opportunities for investors who act early. See the investment blueprint for navigating the AI displacement now $182-billion life sciences solutions, diagnostics, and analytical instruments company Thermo Fisher Scientific (NYSE: TMO) has had a difficult start to 2026, with shares down more than 15% year-to-date (YTD) and the company recently dipping into TradeSmith's red zone for financial health. A substantial portion of that recent sluggishness may be tied to tariffs and FX volatility, which combined to reduce margins by over 100 basis points in 2025. There are, however, several bright spots in Thermo Fisher's recent performance. In Q4 2025, revenue of $12.2 billion rose 7% year-over-year (YOY), beating analyst expectations by roughly $250 million. Adjusted earnings per share (EPS) also topped forecasts at $6.57. That momentum may reflect several notable product launches in recent months, including the Orbitrap Astral Zoom mass spectrometer and new bioreactor offerings. Ultimately, Thermo Fisher's broad business model and diverse product portfolio could provide sufficient cushion against external pressures. Even if guidance for 2026 is modest, with revenue expected to increase 4% to 6% for the year, expected improvements to EBITDA margin are a welcome tailwind, and underlying customer demand should remain solid. This may explain why analysts continue to favor TMO shares: 17 out of 19 rate the company a Buy or equivalent, and consensus estimates imply more than 29% upside potential. Danaher's Business May Be Improving, Even as Guidance Remains Modest Danaher Corp. (NYSE: DHR) shares are down almost 20% YTD, putting the instruments, consumables, and reagents firm in a similar spot to Thermo Fisher. Though 2026 guidance calls for modest core revenue growth of 3% to 6% YOY, that masks a solid latest quarter that included top- and bottom-line beats and $5.3 billion in free cash flow for 2025. Two key bright spots for 2026 are Danaher's bioprocessing business—expected to deliver high-single-digit revenue growth thanks to strong monoclonal antibody demand—and diagnostics. Diagnostics is likely to benefit from recent FDA clearances, and equipment orders have begun to improve after a prolonged weak period, which could further drive sales growth. Analysts are fairly optimistic about DHR, forecasting roughly 12.3% earnings growth over the coming year and around 35% potential upside in the share price. This optimism is reflected in ratings: 19 out of 22 analysts rate DHR shares as Buys. Agilent's Biocare Purchase Could Be a Catalyst Agilent Technologies (NYSE: A) appears a step behind the companies above based on its latest earnings, which showed tepid 4.4% YOY revenue growth and slight misses on both earnings and revenue versus analyst expectations. Still, Agilent may have a growth engine in its recent acquisition of Biocare Medical, which should strengthen its position in cancer diagnostics. Although Biocare's price tag was about $1 billion, the deal should add a new source of recurring revenue in an area with growing demand. Cancer diagnostics can also be a higher-margin business than some of Agilent's existing operations, which could help improve its operating margin (24.6% in the last quarter). Despite a decline of about 17% YTD, Agilent shares have roughly 42% upside potential, according to analysts. Wall Street rates the stock a Moderate Buy overall, with 13 of 16 ratings classified as Buy or equivalent. | 
